Escrihuela Vidal, FrancescBerbel, DàmarisFernández Hidalgo, NuriaEscolà Vergé, LauraMuñoz, PatriciaOlmedo Samperio, MaríaGoenaga Sánchez, Miguel ÁngelGoikoetxea Agirre, Ane JosuneFariñas, María CarmenAlarcón, Aristides deMiró Meda, José M. (José María), 1956-Ojeda Burgos, GuillermoPlata, AntonioCuervo Requena, GuillermoCarratalà, JordiGAMES Investigators.2024-03-062024-06-222023-06-221058-4838https://hdl.handle.net/2445/208469Background: Evidence supporting combination treatment with a beta-lactam plus an aminoglycoside (C-BA) for endocarditis caused by viridans and gallolyticus group streptococci (VGS-GGS) with intermediate susceptibility to penicillin (PENI-I) is lacking. We assessed the clinical characteristics and outcomes of PEN-I VGS-GGS endocarditis and compared the effectiveness and safety of C-BA with third-generation cephalosporin monotherapy. Methods: Retrospective analysis of prospectively collected data of a cohort of definite endocarditis caused by penicillin-susceptible and PENI-I VGS-GGS (penicillin minimum inhibitory concentration ranging from 0.25 to 2 mg/L) between 2008 and 2018 in 40 Spanish hospitals. We compared cases treated with monotherapy or with C-BA and performed multivariable analyses of risk factors for in-hospital and 1-year mortality. Results: A total of 914 consecutive cases of definite endocarditis caused by VGS-GGS with complete or intermediate susceptibility to penicillin were included. A total of 688 (75.3%) were susceptible to penicillin and 226 (24.7%) were PENI-I. Monotherapy was used in 415 (45.4%) cases (cephalosporin in 331 cases) and 499 (54.6%) cases received C-BA. In-hospital mortality was 11.9%, and 190 (20.9%) patients developed acute kidney injury. Heart failure (odds ratio [OR]: 6.06; 95% confidence interval [CI]: 1.37-26.87; P = .018), central nervous system emboli (OR: 9.83; 95% CI: 2.17-44.49; P = .003) and intracardiac abscess (OR: 13.47; 95% CI: 2.24-81.08; P = .004) were independently associated with in-hospital mortality among PEN-I VGS-GGS cases, while monotherapy was not (OR: 1.01; 95% CI: .26-3.96; P = .982). Conclusions: Our findings support the use of cephalosporin monotherapy in PEN-I VGS-GGS endocarditis in order to avoid nephrotoxicity without adversely affecting patient outcomes.26 p.application/pdfeng(c) Escrihuela-Vidal, F. et al., 2023Infeccions per estreptococsCefalosporinesMedicaments antibacteriansPenicil·linaEndocarditisStreptococcal infectionsCephalosporinesAntibacterial agentsPenicillinEndocarditisinfo:eu-repo/semantics/article7408942024-03-06info:eu-repo/semantics/openAccess937439737345869